Withdrawal of FY25 guidance

• Althea Group sells pharmaceutical brand assets to Tasmanian Botanics
• Sale enables Althea to focus on high-growth North American THC beverage market
• Previously issued FY25 revenue and EBITDA guidance no longer applicable

Althea Group Holdings Ltd (ASX:AGH) has announced the withdrawal of its previously issued revenue and EBITDA guidance for the financial year ending 30 June 2025. This decision follows the company's announcement regarding the sale of key pharmaceutical assets from its wholly-owned subsidiary, Althea Company Pty Ltd, to Tasmanian Botanics Pty Ltd. The divested assets include trademarks, brand goodwill, website, and pharmacy/prescriber data. The now-withdrawn guidance, originally released on 13 February 2025, projected revenue between $26 million and $33 million, alongside adjusted positive EBITDA between $0.8 million and $1.1 million. However, due to the sale of these pharmaceutical brand assets, these forecasts no longer align with AGH's continuing operations. This strategic divestment represents a pivotal milestone in AGH's transformation, enabling the company to fully dedicate resources and capital to the high-growth North American THC-infused beverage market. AGH's subsidiaries, Peak Canada and Peak USA, are well-positioned to lead this emerging category, supported by scalable infrastructure and proprietary Envision™ Emulsion technology. As AGH sharpens its focus on the THC beverage sector, the Board considers it prudent to withdraw financial guidance to reflect the company's streamlined portfolio and evolving growth trajectory.